by John Conrad | Aug 8, 2025 | iBIO in the News
Of the $1.24 billion in venture investments pumped into Illinois’ life sciences sector last year, about half went to the state’s late-stage companies, Series A rounds accounted for 35% and early-stage companies collected 15% of the funding, according to a...
by John Conrad | Aug 5, 2025 | iBIO News
Report highlights nearly 100 life science companies and investment trends as Chicago prepares to welcome BIO International Convention 2030 CHICAGO, IL – August 5, 2025 – The Illinois Biotechnology Innovation Organization (iBIO) today released its inaugural Member...
by John Conrad | Aug 4, 2025 | Policy News
Illinois companies stand to lose $90 million in annual funding if federal programs expire September 30th Illinois life sciences companies and associations have until August 15th to sign onto a group letter urging the state’s Congressional Delegation to...
by John Conrad | Aug 1, 2025 | Member News, NewsBrief
Chicago biotech startup ClostraBio has secured GRAS (Generally Recognized as Safe) status for its flagship probiotic ingredient CLB101™, clearing the path for the first commercially available strain of Anaerostipes caccae in the U.S. What Makes It Different Unlike...
by John Conrad | May 12, 2025 | Policy News
“The President’s Most Favored Nation proposal represents a catastrophic misstep for American biosciences innovation and patient access to life-saving treatments,” said John Conrad, President and CEO of the Illinois Biotechnology Innovation Organization. “This...
